---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-107161"
form_type: "8-K"
ticker: "REGN"
cik: "0000872589"
company_name: "REGENERON PHARMACEUTICALS, INC."
filed_at: "2023-10-05T23:59:59+00:00"
generated_at: "2026-06-10T04:25:05.205467+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Regeneron expects $100M pre-tax IPR&D charge in Q3 2023 from Alnylam milestone

## Summary
- Acquired IPR&D charge of $100M pre-tax due to clinical milestone for ALN-APP Alzheimer's program.
- Charge expected to reduce GAAP and non-GAAP diluted EPS by approximately $0.78 in Q3 2023.
- Milestone relates to collaboration with Alnylam Pharmaceuticals (ALNY) for early-onset Alzheimer's therapy.
- Results for Q3 not finalized; actual amounts may differ from preliminary estimates.

## SEC filing metadata
- accession: 0001104659-23-107161
- form_type: 8-K
- ticker: REGN
- cik: 0000872589
- company_name: REGENERON PHARMACEUTICALS, INC.
- filed_at: 2023-10-05T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/872589/000110465923107161/0001104659-23-107161-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/872589/000110465923107161/tm2327767d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-107161
- JSON: https://secwatch.observer/filing/0001104659-23-107161.json
- Plain text: https://secwatch.observer/filing/0001104659-23-107161.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.